Altimmune’s Next-Gen GLP-1 Curbs Heavy Drinking in Unequivocal Phase 2 alcohol use disorder win on July 28, 2026 Agonist Alcohol Use Disorder Altimmune drinking levels GLP-1/glucagon heavy drinking pemvidutide registrational Risk tolerability United States Food and Drug Administration Weight Loss World Health Organization +
NeOnc Technologies Reports Updated Clinical Results for Intranasal NEO100 on December 16, 2025 clinical results Compassionate Use Intranasal approach NEO100 NeOnc Technologies NTHI Overall Survival radiographic remission recurrent astrocytoma World Health Organization +
WHO to Develop Guidelines for Gilead's Twice-Yearly HIV PrEP Injection (Lenacapavir) on July 14, 2025 Approved Gilead Guidelines HIV prevention Lenacapavir PREP gene twice-yearly injection United States Food and Drug Administration World Health Organization +
Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot on June 20, 2025 Approved Gilead Guidelines HIV prevention Lenacapavir long-acting injectable PREP gene twice-yearly injection United States Food and Drug Administration World Health Organization Yeztugo +